Clinical trials: Tirzepatide
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Obesity
A Study of BGM0504 in Participants With Obesity
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
- Trial name
- NCT06911203
- Testing
- BGM0504, Tirzepatide
- Where
- China
- Volunteers
- 96 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Heart Failure, Diabete Type 2
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1).
- Conditions
- Heart Failure, Diabete Type 2, Arterial Hypertension
- Trial name
- ICDDTKZ26 (NCT07303556)
- Testing
- Tirzepatide (Mounjaro), dapagliflozin, empagliflozin, metformin
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Nazarbayev University
Weight Loss, Weight Gain
Role Of Metabolic Adaptation In Weight Regain
In a previous study (NCT04081337), 55 participants with obesity participated on a 18-week lifestyle intervention to reduce their body weight, targeting 10% body weight loss.
- Conditions
- Weight Loss, Weight Gain, Obesity
- Trial name
- EXPEND-FU (NCT05766358)
- Testing
- Intensive lifestyle change therapy, Tirzepatide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pennington Biomedical Research Center
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-4 (NCT03730662)
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 216 sites in United States, Argentina and 13 more
- Volunteers
- 2,002 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis (PsA), Obesity & Overweight
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and…
- Trial name
- COMBAT-PsA (NCT07443956)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 4 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- NHS Greater Glasgow and Clyde
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
The purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to remove it.
- Trial name
- NCT03322631
- Testing
- Tirzepatide
- Where
- 2 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Crohn Disease
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive…
- Trial name
- NCT06774079
- Testing
- Tirzepatide, Mediterranean diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
- Trial name
- SURPASS-3 (NCT03882970)
- Testing
- Tirzepatide, Insulin Degludec
- Where
- 122 sites in United States, Argentina and 11 more
- Volunteers
- 1,444 people
- Sponsor
- Eli Lilly and Company
Healthy
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT05810597
- Testing
- Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Tirzepatide in the Treatment of Cannabis Use Disorder
Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD).
- Trial name
- NCT07671248
- Testing
- Tirzepatide
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- McMaster University
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Participants
This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC)…
- Trial name
- NCT03375463
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
- Trial name
- NCT07000955
- Testing
- Tirzepatide, IBI362
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Obesity & Overweight, Cardiometabolic Health Indicators
Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
The purpose of this research is to compare weight loss among 3 groups: 1. people who stay on a GLP-1 drug at full strength (Group 1) 2.
- Trial name
- OFF-RAMP (NCT07832084)
- Testing
- GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jing Luo
Healthy
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen.
- Trial name
- NCT04050670
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Obesity
GLP-1s to Enhance Lasting Optimal Weight
The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period.
- Trial name
- GLOW (NCT06861439)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Obesity, Overweight
A Study of LY3841136 in Overweight and Obese Participants
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
- Trial name
- NCT06345066
- Testing
- Tirzepatide, LY3841136
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Eli Lilly and Company